Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMD Serono
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants who had completed the 24-week treatment period of study EMR-700461-023 (ADDRESS II core trial)
Women of childbearing potential who had a negative pregnancy test
You may not be if
Active neurological symptoms of SLE that were deemed severe or progressive
Diagnosis of any demyelinating disease, such as, but not restricted to, multiple sclerosis (MS) or optic neuritis
Pregnancy
Active clinically significant viral, bacterial, or fungal infection, or any major episode of infection that in the investigator's opinion makes the participants unsuitable to continued participation in the study
Clareo Health | Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
